ADPKD患者尿TIMP-2与IGFBP7水平与疾病严重程度不相关
本研究为横断面分析,在296例不同CKD分期的常染色体显性多囊肾病(ADPKD)患者和71例健康对照中检测尿TIMP-2与IGFBP7。结果显示ADPKD患者尿TIMP-2和IGFBP7水平未升高或趋向更低,且与CKD分期无关,校正尿肌酐、尿渗透压、年龄、性别和尿蛋白后仍无差异。
要点
- ADPKD患者尿TIMP-2和IGFBP7水平不高于健康对照,甚至趋向更低。
- 两标志物在不同CKD分期之间无差异,且校正后仍无关联。
- 尿TIMP-2和IGFBP7不适用于评估ADPKD疾病严重程度。
核心结论
- ADPKD患者尿TIMP-2和IGFBP7水平未升高,且与疾病严重程度不相关。
研究设计与样本
- 横断面分析,纳入296例不同CKD分期的ADPKD患者和71例健康对照。
- 采用酶联免疫吸附法测定储存的 spot 尿样本中TIMP-2和IGFBP7。
- 肾功能的评估使用CKD-EPI方程,患者按KDOQI的CKD分类进行分层。
- 部分患者通过MRI测量了总肾脏体积(TKV)。
主要发现
- ADPKD患者(45.5 ± 11.5岁,51.0%女性,血清肌酐106 [85-147] μmol/l)尿TIMP-2和IGFBP7水平与健康对照(46.5 ± 18.5岁,72.6%女性)相比未升高或趋向更低。
- 尿TIMP-2和IGFBP7水平在不同CKD分期之间无差异。
- 校正尿肌酐或尿渗透压后,以及多变量分析中校正年龄、性别和尿蛋白后,上述无差异的结果仍然不变。
临床怎么用
- 不推荐将尿TIMP-2和IGFBP7用于评估ADPKD患者的疾病严重程度或风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation and variable renal function decline that frequently leads to end-stage renal failure. With the advent of renoprotective treatment, there is renewed interest in noninvasive biomarkers to help identify patients at risk of rapid disease progression at early stages. Urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been validated as early markers of acute kidney injury. Because these markers are associated with tubular damage, we studied the performance of both markers in a cohort with chronic tubular pathology. We investigated whether these biomarkers may be useful to evaluate disease severity in ADPKD. METHODS: In a cross-sectional analysis, we measured TIMP-2 and IGFBP7 in stored spot urine samples of patients with ADPKD with various stages of chronic kidney disease (CKD) and healthy controls by enzyme-linked immunosorbent assay. Renal function was estimated using the CKD-Epidemiology Collaboration equation. Patients were stratified according to the Kidney Disease Outcomes Quality Initiative classification for CKD. In a subset of patients, total kidney volume (TKV; using magnetic resonance imaging [MRI]) was measured. RESULTS: In 296 patients with ADPKD (45.5 ± 11.5 years, 51.0% female, serum creatinine 106 [85-147] μmol/l), urine levels of TIMP-2 and IGFBP7 were not increased or tended to be lower as compared with 71 healthy controls (46.5 ± 18.5 years, 72.6% female). The levels did not differ across CKD stages, which remained so after correcting for urine creatinine or osmolality, and for age, sex, and urine protein in multivariable analyses. CONCLUSIONS: Urinary levels of TIMP-2 and IGFBP7 were not higher in patients with ADPKD, and did not correlate with disease severity.
引用
- Dekker SEI, Ruhaak LR, Romijn FPHTM, et al. Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor-Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients. Kidney Int Rep. 2019. PMID: 31194166. doi:10.1016/j.ekir.2019.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。